Apr 16, 2024, 00:17
Paolo Tarantino: We review best practices and future perspectives for the identification of patients with HER2-low Breast Cancer
Paolo Tarantino, Medical Oncologist and Research Fellow at Dana-Farber Cancer Institute, posted on LinkedIn:
“In our latest article, just published on ESMO Open, we review best practices and future perspectives for the identification of patients with HER2-low Breast Cancer.
Thanks to AstraZeneca for supporting this publication and to H. Earle for bravely sharing with us and the journal readers her personal experience while receiving treatment with T-DXd.
See link here.”
Source: Paolo Tarantino/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 19:25
Nov 13, 2024, 16:51
Nov 13, 2024, 16:49
Nov 13, 2024, 16:45
Nov 13, 2024, 16:25
Nov 13, 2024, 16:23
Nov 13, 2024, 16:08